Core Insights - Niagen Bioscience Inc. reported strong financial performance for 2025, with net revenue of $129.4 million, reflecting a 30% year-over-year growth, and a net income of $17.4 million [5][25][30] - The company is well-positioned for 2026, despite increased competition in the NAD market, and continues to lead in NAD science with significant research backing [6][13] - The company has secured a patent for NIAGEN Plus, which will expand its product offerings into intravenous and injectable formulations, and plans to launch at-home injection kits in 2026 [8][9] Financial Performance - In Q4 2025, revenue reached $33.8 million, a 16% increase from the previous year, driven primarily by e-commerce sales [5][27] - Gross margin improved to 64.3% for the full year, indicating enhanced operational efficiency [25] - Selling and marketing expenses were 30.8% of sales in Q4, reflecting targeted investments in brand awareness [29] Research and Development - Niagen Bioscience Inc. remains the global leader in NAD science, with 29 studies published since the last earnings call, including clinical studies demonstrating the benefits of nicotinamide riboside (NR) [6][15] - Notable studies include findings that NR supplementation can slow aging and improve fatigue, sleep quality, and cognitive function [7][16][20] - The company is focusing on the therapeutic potential of NR in neurodegenerative diseases, including ongoing collaborations to explore its preventive effects in Parkinson's disease [18][57] Product Development and Market Expansion - The company plans to expand its presence in the beauty and cosmetics market, following the successful launch of Tru Niagen in beauty [9][46] - Niagen Plus will be introduced in over 1,200 health clinics, with plans to partner with telehealth providers for distribution [8][9] - The company is also exploring new retail channels and international markets, particularly in Asia and the EU [46] Legal and Regulatory Environment - Niagen Bioscience Inc. is currently involved in litigation against the FDA regarding the marketing of NMN as a dietary supplement, believing it has a strong case [10][55] - The company has acquired patents for multiple NR salt forms, enhancing its intellectual property portfolio and market position [11]

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $33.8 million, a 16% year-over-year increase, with net income of $4.1 million [10] - For the full year 2025, net revenue reached $129.4 million, representing a 30% growth year-over-year, and net income was $17.4 million [10][38] - The company ended the year with $64.8 million in cash and no debt, indicating strong financial stability [10][43] Business Line Data and Key Metrics Changes - Revenue from the Tru Niagen product line grew by 21% to $27.5 million, driven primarily by e-commerce sales of $20.2 million, which increased by 17% [40] - Niagen ingredient revenue was $5.6 million, up 5% year-over-year, with food-grade sales at $4.7 million and pharma-grade sales at $900,000 [40] - Revenue from B2B distribution partners totaled $7.3 million, supported by strategic partnerships [41] Market Data and Key Metrics Changes - The company is expanding its presence in over 1,200 health clinics and plans to launch at-home Niagen Plus injection kits through a telehealth platform [15] - The company anticipates continued growth in the Asia-Pacific markets and selective retail channels [66] Company Strategy and Development Direction - The company aims to focus on NAD science and intellectual property while exiting non-core activities, as evidenced by the sale of the ChromaDex Reference Standards business [21][45] - Plans include expanding into the beauty cosmetics market and launching new products, including topical products featuring Niagen [16][66] - The company is committed to maintaining its leadership in NAD science and enhancing its product offerings through strategic R&D investments [20][48] Management's Comments on Operating Environment and Future Outlook - Management acknowledged increased competition in the NAD space but emphasized the company's strong foundation and expertise [11] - The company expects to achieve 10%-15% growth in net sales for 2026, with a slight improvement in gross margin [45][46] - Management expressed confidence in the company's ability to deliver value to stakeholders and maintain its market position [48] Other Important Information - The company secured a patent for intravenous and injectable formulations of NR, indicating potential for new product development [15] - Ongoing litigation against the FDA regarding NMN products is expected to have minimal impact on legal expenses [76] Q&A Session Summary Question: Discussion on injections and telehealth platform - Management confirmed that initially, there will be one SKU for injections, targeting the biohacker community and those interested in longevity interventions [53] Question: Guidance for 2026 - Management indicated that the guidance is conservative, reflecting a cautious approach to revenue projections [58] Question: Growth drivers for 2026 - Management expects growth from existing products, new distribution channels, and increased brand awareness [66] Question: Lawsuit against the FDA - Management believes the case will likely result in a summary judgment and is optimistic about a favorable outcome [76] Question: Share repurchase strategy - Management plans to utilize the remaining $9.75 million of the buyback program, viewing it as a good investment at current prices [79]

Financial Data and Key Metrics Changes - The company reported a record revenue of $31.1 million for Q2 2025, representing a 37% increase year over year, and a net income of $3.6 million compared to virtually breakeven a year ago [7][20]. - The cash position at the end of the quarter was $60.5 million with no debt [24]. - Gross margin improved to 65%, up from 60.2% a year ago, driven by lower cost inventory and higher e-commerce sales [22]. Business Line Data and Key Metrics Changes - E-commerce business generated $18.1 million in net sales, a 39% increase year over year [7][21]. - The food grade and pharmaceutical grade Niagen ingredient business grew 135% year over year, with revenue of $7.4 million [8][21]. - TRU NIAGEN revenue increased by 22% to $22.7 million, primarily driven by e-commerce revenues [21]. Market Data and Key Metrics Changes - The company is expanding its presence in wellness clinics, onboarding over 800 clinics nationwide to offer the Niagen Plus product line [8]. - The partnership with Watsons in Hong Kong is contributing to steady revenues, with plans for joint marketing efforts to grow brand presence [22]. Company Strategy and Development Direction - The company is focusing on expanding its Niagen Plus product line and exploring telehealth functionality on its website [9][8]. - A worldwide exclusive license agreement was signed with Haukeland University Hospital for the development of nicotinamide riboside as a potential therapy for Parkinson's disease [17]. - The company aims to maintain its position as the gold standard in NAD science and is committed to scientific innovation in the dietary supplement industry [14][20]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory and strategic goals, highlighting the strong demand for NAD products [19][20]. - The company raised its revenue growth expectation for the full year from 20%-25% to a range of 22%-27% year over year [27]. - Management noted ongoing scrutiny from California regarding outsourcing facility practices but remains optimistic about the partnership with Wells Pharmacy Network [9][10]. Other Important Information - The company has been featured in major media outlets and events, increasing awareness of its products [10][12]. - There is ongoing research into the effects of NAD supplementation on long COVID and fertility, with studies expected to be published soon [15][16][51]. Q&A Session Summary Question: Regarding the initiative for Parkinson's disease - Management indicated that if the NOPARC trial results are positive, they may pivot to nicotinamide riboside triacetate for FDA approval in the U.S. [30][32]. Question: Volume and pricing for NIAGEN IV in clinics - Management noted that while clinics are currently charging high prices for IV experiences, they believe prices need to come down to increase accessibility and volume [36][39]. Question: Steps for treating long COVID - The key milestone to watch is the publication of the Harvard study on NAD supplementation for long COVID, which could lead to a marketing campaign if results are positive [49][54].